)
Abpro Holdings (ABP) investor relations material
Abpro Holdings Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Focuses on developing next-generation antibody therapeutics for severe diseases, primarily in immuno-oncology and ophthalmology, leveraging proprietary DiversImmune® and MultiMab™ platforms.
Lead candidates ABP-102 (HER2/CD3 T-cell engager for solid tumors) and ABP-201 (VEGF/ANG-2 inhibitor for eye diseases) are in preclinical stages, with clinical trials planned for 2026.
Operates through collaborations with global pharmaceutical partners, including Celltrion and Abpro Bio, and holds worldwide or territorial rights to its pipeline assets.
Business model includes licensing, milestone payments, royalties, and profit-sharing from partnered programs.
Financial performance and metrics
As of September 30, 2025, accumulated deficit was $124.6 million; net loss was $8.5 million for the nine months ended September 30, 2025, and $7.2 million for the year ended December 31, 2024.
Revenue is minimal, with $0.2 million recognized in 2024 from research services; no product sales to date.
Operating expenses decreased due to reduced R&D activity and headcount; cash balance as of September 30, 2025, was $328,000.
Company has restated prior financials due to errors in accrued expenses and identified material weaknesses in internal controls.
Use of proceeds and capital allocation
May receive up to $50 million in gross proceeds from the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd.; proceeds intended for working capital and general corporate purposes.
Management has broad discretion over use of funds; actual allocation will depend on operational needs and market conditions.
- TimeTickerHeadlineOpen
- NAZARA
EBITDA and margins rose on IP focus, but regulatory changes led to major impairment losses. - HAPPYFORGE
Stable to growing financials, strong margins, and disciplined IPO fund use with no audit concerns. - RBA
Q3 revenue rose 16.5% in India; Inspira Global to acquire a controlling stake and infuse capital. - 6674
Profits and dividends revised upward on strong battery sales and improved margins. - BOROUGE
$1.1B net profit, 37% EBITDA margin, record sales, and major restructuring drive future growth. - 8059
Record Q3 profits and strong segment growth support an upwardly revised full-year outlook. - 7011
Strong order intake and profit growth drive upward revision of FY2025 forecasts and reflect key divestiture impact. - 9101
Profits fell across most segments, but energy shipping and a major acquisition stood out. - 4626
Double-digit sales and profit growth, revised forecasts, and a stock split impact. - 3401
Major impairments and divestitures drove losses, but Healthcare posted strong growth.
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)